Table 4 Loci and types of mutations conferring RIF resistance in MTB clinical isolates belonging to different genotypes
Loci and types of mutations | Number of MTB isolates with rpoB mutations from HIV - patients | Number of MTB isolates with rpoB mutations from HIV+ patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
BEIJING | LAM | Ural, X1, Haarlem | TOTAL | BEIJING | LAM, Ural | TOTAL | |||||
TOTAL | B0 / W148 | Other | TOTAL | B0 / W148 | Other | ||||||
rpoB 507 Del | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 511, Leu511Pro | 10 | 2 | 8 | 0 | 0 | 10 | 1 | 0 | 1 | 1 | 2 |
rpoB 511, Leu511Arg, | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 512 Ser512Thr | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
rpoB 512 Ser512Arg, | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 513 Gln513Lys; Gln513Gly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 516 Asp516Tyr | 7 | 1 | 6 | 1 | 1 | 9 | 0 | 0 | 0 | 0 | 0 |
rpoB 516 Asp516Gly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 516 Asp516Val | 1 | 0 | 1 | 3 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
rpoB 516 Asp516Glu | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 516 Asp516Ala | 6 | 1 | 5 | 0 | 0 | 6 | 1 | 0 | 1 | 0 | 1 |
rpoB 522 Ser522Leu | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
rpoB 526 His526Tyr | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
rpoB 526 His526Asn | 1 | 0 | 1 | 5 | 0 | 6 | 0 | 0 | 0 | 1 | 1 |
rpoB 526 His526Leu | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
rpoB 526 His526Pro | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
rpoB 526 His526Arg; His526Asp; His526Cys; His526Glu; His526Gln; His526Pro | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 531 Ser531Leu | 153 | 54 | 99 | 12 | 2 | 167 | 51 | 25 | 26 | 0 | 51 |
rpoB 531 Ser531Asn; Ser531Cys; Ser531Trp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
rpoB 533 Leu533Pro | 7 | 6 | 1 | 0 | 0 | 7 | 1 | 1 | 0 | 6 | 7 |
 TOTAL | 188 | 65 | 123 | 23 | 4 | 215 | 54 | 26 | 28 | 8 | 62 |